

DESCRIPTION

Source Human embryonic kidney cell, HEK293-derived
Asp25-Ser262, with a C-terminal 6-His tag
Accession # Q68D85

N-terminal Sequence Analysis Asp25

Predicted Molecular Mass 28 kDa

SPECIFICATIONS

SDS-PAGE 51-63 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA.
When Recombinant Human B7-H6 is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Human NKp30/NCR3 Fc Chimera (Catalog # 1849-NK) that produces 50% of the optimal binding response is 0.02-0.1 µg/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 200 µg/mL in PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

B7-H6 is a glycosylated member of the B7 family of immune co-stimulatory proteins (1, 2). Mature human B7-H6 consists of a 238 amino acid (aa) extracellular domain (ECD) that contains one Ig-like V domain and one Ig-like C1 domain, a 21 aa transmembrane segment, and a 171 aa cytoplasmic domain that contains one ITIM, one SH2, and one SH3 motif (3). Both of the Ig-like domains carry N-linked glycosylation (4). Within the ECD, human B7-H6 shares 99%, 94%, and 87% aa sequence identity with chimpanzee, orangutan, and gibbon B7-H6, respectively, and 53%-56% with bovine, canine, and equine B7-H6. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells (4, 5). It does not show binding to NKp44, NKp46, or NKG2D (3, 6). Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytotoxicity (3). B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors (3, 7). The expression of NKp30 ligands on tumor cells correlates with tumor cell sensitivity to NKp30-dependent cell lysis (7).

References:

1. Zou, W. and L. Chen (2008) Nat. Rev. Immunol. **8**:467.
2. Bour-Jordan, H. *et al.* (2011) Immunol. Rev. **241**:180.
3. Brandt, C.S. *et al.* (2009) J. Exp. Med. **206**:1495.
4. Li, Y. *et al.* (2011) J. Exp. Med. **208**:703.
5. Joyce, M.G. *et al.* (2011) Proc. Natl. Acad. Sci. **108**:6223.
6. Arnon, T.I. *et al.* (2006) Semin. Cancer Biol. **16**:348.
7. Byrd, A. *et al.* (2007) PLoS ONE **2**:e1339.